logo
Plus   Neg
Share
Email

Icon Bioscience Reports Phase 3 Data For IBI-10090 - Quick Facts

Icon Bioscience Inc. announced that Phase 3 data showed significantly positive outcomes for IBI-10090 compared to placebo in treating inflammation associated with cataract surgery. The company reported that the ensuing analysis of data showed IBI-10090 - with regard to both primary and secondary study endpoints - to be safe as well as highly effective.

The Phase 3 study of IBI-10090 was a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial involving 394 patients.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Intel Corp. (INTC), the world's biggest chipmaker, Thursday said its profit and revenues for the fourth quarter trumped Wall Street estimates. The company's shares gained nearly 7 percent driven by strong outlook for the first quarter and full year 2020. Santa Clara, California-based Intel reported... ABH Pharma, Inc. and Stocknutra.com Inc. have recalled all of its dietary supplement products pursuant to a consent decree entered by the U.S. District Court for the Eastern District of New York. The companies have recalled all dietary supplement products manufactured and sold between January 2013... New York-based grocery chain Fairway Market has filed for Chapter 11 bankruptcy protection, but said its stores will remain open across the Tri-State area during the court process and it does not expect any service interruptions. This is the second time the company has filed for bankruptcy. The company earlier filed for Chapter 11 bankruptcy protection in 2016.
Follow RTT
>